Benzylthiazolidinone Derivatives Useful for the Treatment of Schizophrenia

Abstract

The present invention describes benzylthiazolidinone derivatives and pharmaceutical compositions comprising the same; these compounds have shown activity in schizophrenia animal models, with the advantage of not causing the typical adverse effects of antipsychotic drugs, since they exhibited lower incidence of catatonia and weaker effects on motor coordination, when compared with other antipsychotic drugs, such as haloperidol and clozapine, and no central nervous system depression effect; the molecules showed an effect in models of apomorphine-induced climbing, ketamine-induced hyperlocomotion and in prepulse startle response inhibition. FPY-3 did not exhibit any toxic effects after 14 days of treatment, and is potentially useful for the treatment of schizophrenia.